There are about 6,000 diseases identified as “rare” affecting approximately 300 million people worldwide.
We in the pharmaceutical industry have much to learn from these patients about the challenges they face to achieve their best health and well-being, especially from patients’ real voice.
Innovation starts from the passion to know.
I hope we take Rare Disease Day as an opportunity to learn about these patients’ journey to find the right diagnoses and care for themselves and their families.
We believe our pursuit of innovation and exploration of scientific discovery will deliver life-changing value for those living with rare diseases and bring smiles to our patients.
Masashi Miyamoto
Chief Executive Officer, Kyowa Kirin

More Kyowa Kirin "Patients" Stories
What is the Kyowa Kirin Group’s health and productivity management initiative, Wellness Action 2025?
People & Culture | February 10, 2025

Rare Disease Day 2025 - More Than You Can Imagine
Patients | February,7, 2025

Kyowa Kirin CEO Miyamoto’s New Year Message: Accelerate Our Reforms with Determination for Delivering Life-changing Value to Patients
Growth | January 14, 2025

Kyowa Kirin Hosted Booth at Tokyo Rainbow Pride 2024 for a Second Year in a Row: Initiatives for Accelerating DE&I and the Ideal State a Company Should Strive to Be (Part One)
People & Culture | October 15, 2024

Kyowa Kirin Hosted Booth at Tokyo Rainbow Pride 2024 for a Second Year in a Row: Initiatives for Accelerating DE&I and the Ideal State a Company Should Strive to Be (Part Two)
People & Culture | October 15, 2024

Strengthening our training framework to tackle the biopharmaceutical engineer shortage
People & Culture | September 20, 2024

Highlighting Kyowa Kirin's initiatives across regions for PRIDE MONTH 2024
People & Culture | September 13, 2024

Bio Adventure: Kyowa Kirin’s works with local communities on project to foster future scientists
People & Culture | August 9, 2024

PRIDE MONTH Message from Jeremy Morgan, President, Kyowa Kirin International plc (EMEA region)
People & Culture | July 5, 2024

Kyowa Kirin launches the CTCL Global Care Collaborative’s Time to Act global consensus statement
Patients | May 13, 2024

Kyowa Kirin Global Corporate Planning Head Shoko Itagaki’s Message for International Women's Day
People & Culture | March 8, 2024

Kyowa Kirin CEO Miyamoto’s New Year Message
Growth | January 9, 2024

Kyowa Kirin Chief International Business Officer Abdul Mullick’s Message on UN’s International Day of Persons with Disabilities
Sustainability | December 1, 2023

Kyowa Kirin hosted a booth for the first time at the Tokyo Rainbow Pride 2023 [Our Diversity, Equity & Inclusion]
People & Culture | November 9, 2023

Our Stable Supply of High-quality Pharmaceuticals
Sustainability | September 20, 2023

Provide pharmaceuticals for unmet medical needs - A Conversation with Kyowa Kirin’s R&D Executives
Innovation | August 22, 2023

Ensure a Thriving Global Environment for Future Generations
Sustainability | July 28, 2023

“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅡ
People & Culture | June 9, 2023

“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅠ
People & Culture | April 25, 2023

Kyowa Kirin CEO Miyamoto’s Message on Rare Disease Day
Patients | February 28, 2023

Promoting patient advocacy and nurturing patient-centric care: Interview with Kyowa Kirin North America
Patients | February 14, 2023

Celebrating another year of diverse initiatives around the world: RDD 2022 in EMEA
Patients | January 24, 2023

Celebrating another year of diverse initiatives around the world: RDD 2022 in North America
Patients | December 15, 2022

Celebrating another year of diverse initiatives around the world: RDD 2022 in Asia Pacific
Patients | November 21, 2022

Celebrating another year of diverse initiatives around the world: RDD 2022 in Japan
Patients | October 20, 2022

Providing high-quality pharmaceuticals to patients around the world
Sustainability | September 22, 2022

Striving to create life-changing “Only-one value” that brings smiles to patients
Innovation | July 25, 2022

Kyowa Kirin International: It's Time to Shine A Light on XLH
Patients | June 27, 2022

Kyowa Kirin CEO Miyamoto’s Message on Pride Month
People & Culture | June 9, 2022

Kyowa Kirin International Celebrates the UN’s International Day of Persons with Disabilities in EMEA
People & Culture | January 20, 2022

Kyowa Kirin International: Around the world challenge
People & Culture | December 17, 2021

Kyowa Kirin North America: Honoring The Caregiver, Everyday Heroes, During National Family Caregivers Month
Patients | November 19, 2021

Kyowa Kirin's Effort to Realize a Sustainable Society
Sustainability | October 11, 2021

Our Financial Strategy for Creating Life-changing Value
Growth | September 9, 2021

Changes in society caused by COVID-19 and the impact on Kyowa Kirin
Growth | August 19, 2021

Bio Adventure Hands-On Experience Sessions: Become a drug discovery researcher During Your Summer Break
Sustainability | July 27, 2021

AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS
News Release | June 1, 2021

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting
News Release | May 20, 2021

White Paper on the unrecognized burden of XLH in adults in Europe
Patients | July 13, 2020

Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (First Half)
People & Culture | March 5, 2020

Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (Second Half)
People & Culture | March 5, 2020

“Delivering smiles with sports” Creating an inclusive society through table tennis
Sustainability | January 14, 2020

Bio Adventure*: Kyowa Kirin Invites Children to a Science Adventure
People & Culture | July 3, 2019
